Back to Search
ZENA KNIGHT, MD
MD
Anesthesiology Physician
NPI: 1639564537IndividualAccepts Medicare
Specialties, Licenses & Credentials
Critical Care Medicine (Anesthesiology) Physician
Anesthesiology — Critical Care Medicine
Code: 207LC0200X
A144587(CA)
Anesthesiology PhysicianPrimary
Anesthesiology
Code: 207L00000X
A144587(CA)
CMS Specialties
PrimaryANESTHESIOLOGY
Education
HARVARD MEDICAL SCHOOL
Class of 2015
Research & Publications (20)
Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production.
PMID 19014771·J Allergy Clin Immunol·2008
7-preclinical
A remodelled protease that cleaves phosphotyrosine substrates.
PMID 17803306·J Am Chem Soc·2007
8-other
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.
PMID 16647110·Cell·2006
7-preclinical
The use of the 'corrective emotional experience' and the search for the bad object in psychotherapy.
PMID 15895767·Am J Psychother·2005
8-other
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.
PMID 15358300·Bioorg Med Chem·2004
8-other
Phosphospecific proteolysis for mapping sites of protein phosphorylation.
PMID 12923550·Nat Biotechnol·2003
8-other
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
PMID 19318683·Blood·2009
8-other
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
PMID 19209957·PLoS Biol·2009
7-preclinical
EGFR signals to mTOR through PKC and independently of Akt in glioma.
PMID 19176518·Sci Signal·2009
8-other
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
PMID 19147570·Cancer Res·2009
8-other
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
PMID 18922908·Cancer Res·2008
7-preclinical
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
PMID 18849971·Nat Chem Biol·2008
4-observational
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
PMID 18829572·Cancer Res·2008
8-other
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
PMID 18704194·J Clin Invest·2008
7-preclinical
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.
PMID 18691552·Cancer Cell·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 300 PASTEUR DR
STANFORD, CA 94305 - Phone
- (650) 723-4000
Quick Facts
- NPI
- 1639564537
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 11
- Publications
- 20
Are you this provider?
Claim Your Profile